The FDA removed most of the HRT black box warning. Here is what changed and what stayed.

Short answer

On November 10, 2025, FDA asked the makers of menopausal hormone therapy to remove statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning on their labels. FDA approved the first six updated labels on February 12, 2026, and three estradiol patch labels followed on October 30, 2026. The boxed warning about endometrial cancer stays on systemic estrogen-alone products. The change is to the safety wording on FDA-approved product labels. It does not change what any program charges, and the prices on this site are recorded separately with a read date.

Timeline

What was removed

• From the boxed warning on all menopausal hormone therapy products, systemic and local vaginal: the statements about cardiovascular disease, breast cancer and probable dementia.
• From the boxed warning: the recommendation to use the lowest effective dose for the shortest amount of time.
• From the whole label: the probable dementia warning.

What stayed

• The boxed warning about endometrial cancer stays on systemic estrogen-alone products. Endometrial cancer language is removed from the boxed warning of the other product types.
• Information about cardiovascular disease and breast cancer stays in the warnings section of systemic product labels. It moved out of the box; it did not leave the label.

What was added

• For systemic products: a statement that starting hormone therapy can be considered for moderate to severe hot flashes and night sweats in women younger than 60 or within 10 years of menopause.
• For systemic products: Women's Health Initiative data for women aged 50 to 59.
• For local vaginal products: shorter, condensed safety information.

Which labels have been updated so far

FDA's list, current as of October 30, 2026, shows updated prescribing information for these products:

Products not on the list may still carry the older wording until their own updates are approved. The list is here: Menopausal hormone therapies with updated prescribing information (opens in a new tab).

Does this apply to compounded hormones?

The label changes concern FDA-approved products and their prescribing information. Compounded hormone preparations, including the compounded estradiol and progesterone creams some online programs sell, are not FDA-approved and do not carry FDA-approved labeling, so this update does not describe them. If you are comparing programs, ask which product you would receive: an FDA-approved product or a compounded preparation.

Why estradiol patches can be hard to find

In its September 3, 2026 update, FDA said the supply of FDA-approved estradiol patches nearly doubled over the past year, that patches remain available, and that availability of a specific brand can vary by pharmacy. FDA also advised patients not to stop or change a medication without talking to their healthcare provider. Read the update: FDA update on estradiol patch availability (opens in a new tab).

What it means if you are comparing what HRT costs

The label update does not set a price. What you pay still depends on the same things this guide records for every program:

• The preparation. A patch, a tablet, a gel or spray, a cream and a vaginal product are different purchases with different charges. See What patches, tablets and creams cost online.
• The billing cycle. A 28-day charge is not a monthly charge. See The 28-day cycle.
• Labs and visits. Some programs bill them outside the recurring charge. See What "labs included" means.
• Membership. An included membership is still part of the price. See A membership that is "included" is not free.

Then use the Estradiol cost calculator, or the progesterone records.

A program recorded in this guide that is operated by its publisher

Frequently asked questions

• Did the FDA remove the black box warning on HRT?

  Mostly. FDA removed the statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning on menopausal hormone therapy labels. The boxed warning about endometrial cancer stays on systemic estrogen-alone products.

• When did the HRT black box warning change?

  FDA announced the change on November 10, 2025. It approved the first six updated labels on February 12, 2026, and three estradiol patch labels were added to its list by October 30, 2026.

• Does the change apply to vaginal estrogen?

  Yes. The boxed warning changes apply to local vaginal products as well as systemic ones, and vaginal product labels now carry condensed safety information.

• Does the change apply to compounded or bioidentical hormones?

  The change applies to the labeling of FDA-approved products. Compounded hormone preparations are not FDA-approved and do not carry FDA-approved labeling.

• Does removing the black box warning mean hormone therapy is right for me?

  The label change is FDA's updated description of the evidence. Whether hormone therapy suits you depends on your own history and is a decision for you and a licensed clinician.

• Why are estradiol patches hard to find?

  FDA said demand rose after the November 2025 action. In September 2026 it said patch supply had nearly doubled over the past year and that availability of a specific brand can vary by pharmacy.